XBiotech Inc
XBIT
Company Profile
Business description
XBiotech Inc is a United States-based clinical-stage biopharmaceutical company. It is engaged in discovering and developing True Human (antibody technology) monoclonal antibodies for treating a variety of diseases. The company focuses on developing Anti-IL-1 a therapeutic antibody as a treatment for cancer. Geographically, all of its operations are in the United States.
Contact
5217 Winnebago Lane
AustinTX78744
USAT: +1 512 386-2900
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
92
Stocks News & Analysis
stocks
Ask the analyst: Are IDP Education's woes temporary?
The global education services provider has gone from stock market darling to one of the ASX's weakest performers. What gives?
stocks
Is it time to buy the Magnificent Seven?
After the recent selloff, the bull market’s most in-demand stocks look much cheaper.
stocks
Chart of the week: Did ASX companies underwhelm or impress during earnings season?
The Chart of the Week looks at how our Fair Values changes for Australian companies during earnings season.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 7,966.60 | 36.00 | -0.45% |
| CAC 40 | 7,946.97 | 41.99 | -0.53% |
| DAX 40 | 22,523.35 | 153.06 | -0.67% |
| Dow JONES (US) | 41,062.19 | 288.74 | -0.70% |
| FTSE 100 | 8,525.21 | 15.76 | -0.18% |
| HKSE | 23,462.65 | 137.66 | -0.58% |
| NASDAQ | 17,429.04 | 219.41 | -1.24% |
| Nikkei 225 | 36,790.03 | 29.06 | -0.08% |
| NZX 50 Index | 12,209.05 | 40.50 | -0.33% |
| S&P 500 | 5,556.50 | 42.80 | -0.76% |
| S&P/ASX 200 | 7,749.10 | 37.10 | -0.48% |
| SSE Composite Index | 3,358.73 | 13.20 | -0.39% |